Zomedica Inc., an Ann Arbor, Michigan based company focused on animal diagnostics and therapies in the companion animal industry received coverage by PCG Research, the equity arm of PCG Advisory, a leading New York Based investor and advisory firm. PCG Research provided an overview of Zomedica (NYSE: ZOM) and offered a thesis to support its 12-month price target of $1.85 per share.
Jeff Ramson, CEO of PCG Advisory commented on the initiation of Zomedica by saying,
“Zomedica is currently focused on investigating strategies for North America and global commercialization of diagnostics for the companion animal market, as well as developing a therapeutic pharmaceutical pipeline. The company expects initial commercialization activities in its diagnostic product lines to begin during 2020. Its pharmaceutical pipeline and drug delivery methods are in development, and we expect them to begin pivotal studies in the second half of 2019, with additional catalysts and milestones over the next few years.”
He added, “Zomedica is also positioned to make advancements on the corporate development front in coming quarters. We are excited about their addition to our recently launched company sponsored equity research platform and look forward to tracking the company’s progress.”
Highlights from the report detail Zomedica’s near-term opportunities.
* Zomedica is a near commercialization company developing diagnostic and pharmaceutical solutions for the veterinary healthcare market, specifically for companion animals(dogs, cats, and horses). The company’s business model relies on developing novel applications of proven diagnostic and therapeutic solutions that individually target large markets north of $50-100MMthereby considerably lowering regulatory, R&D and ‘go to market’ risk. Further, the company’s solutions allow veterinarians the opportunity to lower costs, reduce time to care and grow revenue while better serving the animals in their care. Revenues are expected to begin in2020 and could rise to nearly $75MM by 2024 (5-year CAGR of~75%)
* Revenues are expected to begin in2020 and could rise to nearly $75MM by 2024 (5-year cagr of~75%).
* Multiple Products To Be Commercialized in2020. The company has 3 diagnostic platforms and 4 therapeutic solutions in development. The diagnostic platforms do not require regulatory approval and all 3 are expected to be launched in 2020. 3 of the 4therapeutic products are expected to begin pivotal studies (equivalent to Phase 3 in human trials) in H2 2019. Revenues could rise from 0 in2019 to $4mm in 2020 and touch $75MM by 2024 and rising at~75%5-yearCAGR.
The coverage report, which was published on Monday, September 10, 2019, can be found in its entirety by clicking HERE.
Copyright © 2019 PCG ResearchBottom of Form